Scientific Program

*It is based on the local time of Seoul, Korea (UTC/ GMT +9:00)

November 21 (Thu)

Educational Session 1 - Targeting RAS in Cancer

Date & Time 11/21(Thu) 08:30 – 10:10 Place Crystal Ballroom (2F)
  • ·
  • Pancreas cancer: KRAS, genomics and clinical actionability

    Eileen M. O’Reilly (Memorial Sloan-Kettering Cancer Center, USA)

  • ·
  • Cell type-specific KRAS mutation in gastric and pancreatic carcinogenesis

    Su-Hyung Lee (Vanderbilt University Medical Center, USA)

  • ·
  • Response and resistance to KRAS inhibition in pancreatic cancer

    Andrew J. Aguirre (Dana-Farber Cancer Institute, USA)

  • ·
  • The way of RAS inhibitors, paved with failures

    Dae Ho Lee (University of Ulsan College of Medicine)

Keynote Lecture

Date & Time 11/21 (Thu) 10:30 – 11:10 Place Crystal Ballroom (2F)
  • ·
  • What makes a stem cell a stem cell and how does it go bad in AML

    John E. Dick (UHN Princess Margaret Cancer Center, Canada)

Luncheon Symposium 1 - Boryung

Date & Time 11/21(Thu) 11:20 - 12:00 Place Crystal Ballroom (2F)
  • ·
  • Moving systemic and radiation therapy before surgery: Total neoadjuvant therapy in rectal cancer

    Jwa Hoon Kim (Korea University College of Medicine)

Luncheon Symposium 2 - ONO/BMS

Date & Time 11/21(Thu) 11:20 - 11:40 Place Sapphire Ballroom (3F)
  • ·
  • CheckMate 649 update: Reinforcing nivolumab plus chemotherapy as the first-line standard treatment for advanced gastric cancer

    Sung Hee Lim (Samsung Medical Center)

Luncheon Symposium 3 - Lilly

Date & Time 11/21(Thu) 11:40 - 12:00 Place Sapphire Ballroom (3F)
  • ·
  • New options for high-risk HR+/HER2- EBC: Increasing the chance for cure

    Valentina Guarneri (University of Padova, Italy)

Plenary Session 1 - Patient Derived Models

Date & Time 11/21 (Thu) 12:30 – 14:10 Place Crystal Ballroom (2F)
  • ·
  • Pharmacoscopy: Image-based ex vivo drug testing for blood and brain cancers

    Berend Snijder (ETH Zurich, Switzerland)

  • ·
  • Cancer research models using patient-derived xenograft(PDX) and PDX-derived organoid(PDXO)

    Jong-Il Kim (Seoul National University College of Medicine)

  • ·
  • Combinatorial functional precision medicine in cancer

    Edward Kai-Hua Chow (KYAN Technologies, Singapore)

  • ·
  • Microscale tools for 3D reconstitution of tumor microenvironment

    Seok Chung (Korea University)

Plenary Session 2 - Tumor Heterogeneity

Date & Time 11/21 (Thu) 14:30 – 16:10 Place Crystal Ballroom (2F)
  • ·
  • Functional interrogation of cancer cell state heterogeneity in solid tumors

    Tuomas Tammela (Memorial Sloan Kettering Cancer Center, USA)

  • ·
  • Modeling cancer timelines to unravel cancer transitions and predict prevention strategies

    Dongkwan Shin (National Cancer Center)

  • ·
  • Tumor heterogeneity as a key to understanding combination therapy

    Adam C. Palmer (University of North Carolina Chapel Hill, USA)

  • ·
  • Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses

    Soon-Chan Kim (Seoul National University College of Medicine)

Proffered Papers Session 1

Date & Time 11/21 (Thu) 16:30 - 17:30 Place Crystal Ballroom (2F)
  • ·
  • Zolbetuximab plus chemotherapy as first-line (1L) treatment in patients with claudin 18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Korean population subgroup—combined efficacy and safety analysis from SPOTLIGHT and GLOW

    Keun-Wook Lee (Seoul National University College of Medicine)

  • ·
  • Proteomic and scRNA-seq insights into the concordance of Helicobacter pylori infection with gastric cancer progression: A 4-protein panel for early diagnosis and risk stratification

    Yu Jin (Peking University Cancer Hospital & Institute, China)

  • ·
  • Transcriptomic interpretation of histopathological characteristics in renal cell carcinoma

    Minjun Kim (McGill University, Canada)

  • ·
  • Regulation of the TM4SF5/SLAMF7 axis by small isoxazole-based small molecules mediates NK cell cytotoxicity against hepatocellular carcinoma

    Jung Weon Lee (Seoul National University)

  • ·
  • Senolytic CAR T cells with cancer-agnostic potential

    Zeda Zhang (Memorial Sloan Kettering Cancer Center, USA)

  • ·
  • IDH-mutant glioma arises from glial progenitor cells harboring the initial driver mutation

    Jung Won Park (KAIST)

Proffered Papers Session 2

Date & Time 11/21 (Thu) 16:30 - 17:30 Place Sapphire Ballroom (3F)
  • ·
  • Mediator subunit Med4 enforces metastatic dormancy in breast cancer

    Seongyeon Bae (Columbia University, USA)

  • ·
  • MultiOmics analysis of breast cancer response to exercise and immunotherapy in mice

    Ngozi Akingbesote (Yale School of Medicine, USA)

  • ·
  • Determining risk-adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors

    Tung Hoang (University of Health Sciences, Vietnam)

  • ·
  • Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study

    Hye In Lee (Asan Medical Center)

  • ·
  • Small extracellular vesicles-GCC2 as prognostic biomarker for early-stage lung adenocarcinoma: A retrospective multicenter study

    Byeong Hyeon Choi (Korea University Guro Hospital)

  • ·
  • Dual targeting of phosphorylated BADS99 and PIM kinase achieves a complete response in advanced epithelial ovarian carcinoma

    Vipul Bhardwaj (Tsinghua Berkeley Shenzhen Institute, China)

November 22 (Fri)

Educational Session 2 - Cancer Neuroscience

Date & Time 11/22(Fri) 08:00 – 09:30 Place Crystal Ballroom (2F)
  • ·
  • The cancer neuroscience of brain tumor networks

    Varun Venkataramani (University Hospital Heidelberg, Germany)

  • ·
  • Regulation of anti-tumoral immunity via brain-bone interactions

    Serkin Park (Korea University College of Medicine)

  • ·
  • Nerve-wracking resistance: How tumor-associated nerves outsmart immunotherapy

    Moran Amit (The University of Texas MD Anderson Cancer Center, USA)

Plenary Session 3 - EBV Related Cancers

Date & Time 11/22 (Fri) 09:40 – 11:20 Place Crystal Ballroom (2F)
  • ·
  • Targeting the vulnerability of EBV infection for vaccine development

    Mu-Sheng Zeng (Sun Yat-Sen University Cancer Center, China)

  • ·
  • EBV-positive gastric cancer: Future perspectives and therapeutic challenges

    Kyoung-Mee Kim (Sungkyunkwan University School of Medicine)

  • ·
  • Adoptive cellular immunotherapy for EBV-associated cancers: A new paradigm in personalized medicine

    Rajiv Khanna (QIMR Berghofer Medical Research Institute, Australia)

  • ·
  • Epstein-Barr virus immunity and a novel cytotoxic CD4+ T cell approach for B cell malignancies

    Il-Kyu Choi (Daegu Gyeongbuk Institute of Science and Technology)

Waun Ki Hong Memorial Lecture

Date & Time 11/22 (Fri) 11:40 – 12:20 Place Crystal Ballroom (2F)
  • ·
  • Target identification in cancer precision medicine

    Yeul Hong Kim (Yuhan Corporation)

Luncheon Symposium 4 - MSD

Date & Time 11/22(Fri) 12:30 - 13:10 Place Crystal Ballroom (2F)
  • ·
  • Pembrolizumab + ADC: Opening new horizons in urothelial cancer treatment

    Jungmin Jo (Ewha Womans University College of Medicine)

Luncheon Symposium 5 - Roche

Date & Time 11/22(Fri) 12:30 - 12:50 Place Sapphire Ballroom (3F)
  • ·
  • A step towards cure: Adjuvant alectinib for resected ALK-positive NSCLC

    Sun Min Lim (Yonsei University College of Medicine)

Plenary Session 4 - AI in Cancer Research and Treatment

Date & Time 11/22 (Fri) 13:40 – 15:20 Place Crystal Ballroom (2F)
  • ·
  • Mapping the landscape of tumor heterogeneity with self-supervised AI

    Aristotelis Tsirigos (New York University School of Medicine, USA)

  • ·
  • Digital pathology and AI for gastrointestinal and hepatobiliary cancers

    Sung Hak Lee (The Catholic University of Korea College of Medicine)

  • ·
  • AI, data science, & MIDRC in medical imaging

    Maryellen L. Giger (University of Chicago, USA)

  • ·
  • Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

    Changhwan Sung (Asan Medical Center)

Plenary Session 5 - Advances in Immuno-oncology

Date & Time 11/22 (Fri) 15:40 – 17:20 Place Crystal Ballroom (2F)
  • ·
  • TILs: The tip of the iceberg for solid tumor adoptive cell therapy

    Allison Betof Warner (Stanford University, USA)

  • ·
  • Conditional activation of T cell in the tumor microenvironment by a Novel 4-1BB T cell engaging BsAb (Grabody T) and phase 1 trial efficacy and safety of ragistomig (ABL503/TJ-L14B; PD-L1x4-1BB BsAb) and givastomig (ABL111/TJ-CD4B; Claudin18.2x4-1BB BsAb)

    Sang Hoon Lee (ABL bio)

  • ·
  • Surpassing the efficacy barriers of TCR T-based strategies

    Aude G. Chapuis (Fred Hutchison Cancer Center, USA)

  • ·
  • Deciphering natural killer cells' secretomes and their influence on immune activation

    Kyung-Soon Park (CHA University School of Medicine)